Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aestus licenses rights to Astellas' FK614 for pain

Executive Summary

Aestus Therapeutics Inc. (neurological diseases) has licensed exclusive global rights to Astellas Pharma Inc.'s FK614 (renamed ATx08001), a diabetes drug candidate that Aestus found has implication in pain, including post-herpetic neuralgia (PHN).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies